



## Apadaz<sup>®</sup> (benzhydrocodone/acetaminophen) – First-time generic (authorized generic)

- On February 25, 2019, KVK Tech/KemPath launched an authorized generic of its [Apadaz \(benzhydrocodone/acetaminophen\)](#) tablets.
- Apadaz is approved for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
- Apadaz carries a boxed warning for addiction, abuse, and misuse; risk evaluation and mitigation strategy (REMS); life-threatening respiratory depression; accidental ingestion; neonatal opioid withdrawal syndrome; cytochrome P450 3A4 interaction; hepatotoxicity; and risks from concomitant use with benzodiazepines or other central nervous system depressants.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.